Design of potent and selective human cathepsin K inhibitors that span the active site
about
Crystal structure of wild-type human procathepsin KLocalization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfonesEmerging techniques for the discovery and validation of therapeutic targets for skeletal diseases.Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin LHydrazide reactive peptide tags for site-specific protein labeling.Targeting polymer therapeutics to bone.Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient miceMolecular dynamics simulations of the catalytic pathway of a cysteine protease: a combined QM/MM study of human cathepsin K.Identification and synthesis of a unique thiocarbazate cathepsin L inhibitorMolecular dynamics studies of caspase-3.Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum.Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft.Evaluation and ranking of enzyme designsThe S2 subsites of cathepsins K and L and their contribution to collagen degradation.Papain-like cysteine proteases.Probing cathepsin K activity with a selective substrate spanning its active site.Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery.Irreversible inhibition of human cathepsins B, L, S and K by hypervalent tellurium compounds.Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR.Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis.A comparison of staphostatin B with standard mechanism serine protease inhibitors.Royal Society of Chemistry and The Biochemical Society's international symposium on functional genomics: from gene to commercial reality? September 19-22, 1999, Ambleside, UK.
P2860
Q27617382-17310E75-DC80-4EBB-94F0-D2665D428700Q28579975-AC5B4BC2-1FF8-4E9B-A05C-6BD77C737FEBQ31120838-DF1F718B-DE46-4392-A120-AEEECB97A16DQ33327656-C14AE61F-2F5C-4390-97E0-92B4CCD282D1Q34015052-288BDF67-1D16-491A-95BA-1B42B1864EA3Q35951743-D964BCC7-15C8-4E99-B83E-72007AB666E6Q36791739-E2DC8E9E-1CDA-4FF8-831E-70EB99184CA0Q36915183-48010FE0-6EE5-4FFD-BD0C-B4B27394DA98Q39035003-9DACB6A9-FF76-4641-A8F3-B94E204EEA80Q40232980-692CF4E9-8D6D-42CC-B435-742E8DECF824Q41745894-688CA145-EA78-4967-9BE9-6129CA550BC0Q41845464-30CCFE43-F500-4501-8A60-68A56FF1D829Q42045610-889360E5-819B-4314-B1B3-4271E9D83778Q42160204-933B3276-FC9D-4006-B319-752BC55606D8Q42169600-5BACC197-9ADA-4124-B003-E6F44D822F5FQ43003155-089A71D7-C244-4DD7-8089-727CB9CABA6FQ43245922-6BEFB5ED-565E-45FA-ACC9-0B49EAD171FDQ43296436-170315C8-A2B4-4AED-A8C0-908C017FCB60Q43517008-1F5F5D20-847D-4B42-AAB5-5F604545F532Q43580089-236418DB-A578-4518-A027-8658F7CFB405Q43959853-75F82AA5-EF0F-44AC-ACBA-520EE367819CQ45219871-78768728-0B76-44DF-BD46-C9F1BBD074BEQ53328791-E03BEC63-49AB-4050-8F83-61480D927DF9
P2860
Design of potent and selective human cathepsin K inhibitors that span the active site
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Design of potent and selective human cathepsin K inhibitors that span the active site
@ast
Design of potent and selective human cathepsin K inhibitors that span the active site
@en
Design of potent and selective human cathepsin K inhibitors that span the active site
@nl
type
label
Design of potent and selective human cathepsin K inhibitors that span the active site
@ast
Design of potent and selective human cathepsin K inhibitors that span the active site
@en
Design of potent and selective human cathepsin K inhibitors that span the active site
@nl
prefLabel
Design of potent and selective human cathepsin K inhibitors that span the active site
@ast
Design of potent and selective human cathepsin K inhibitors that span the active site
@en
Design of potent and selective human cathepsin K inhibitors that span the active site
@nl
P2093
P2860
P356
P1476
Design of potent and selective human cathepsin K inhibitors that span the active site
@en
P2093
B Y Amegadzie
C A Janson
C F Ijames
C R Hanning
D Zembryki
P2860
P304
P356
10.1073/PNAS.94.26.14249
P407
P577
1997-12-23T00:00:00Z